Companion Diagnostics Market

COMPANION DIAGNOSTICS MARKET
Global Market Analysis, Insights, Trends, and Opportunity Inference, 2016-2024
REPORT DESCRIPTION
Global Companion Diagnostics Market: Overview
The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0%
during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple
biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to
improve the time to market for companion diagnostic test products.
Source: Coherent Market Insights Analysis (2016)
The U.S. FDA lays emphasis on regulatory clearance of companion diagnostics, in its recent draft guidance in 2016, before approving any
oncology product that requires and in-vitro diagnostic (IVD) companion diagnostic device for tis safe and effective use. Therefore, drug
developers and diagnostic test manufacturers need to work in close collaborations in order to avoid any regulatory bottlenecks.
AstraZeneca plc struck a deal with Abbott Laboratories, Inc. in 2015 to develop a companion diagnostic test for tralokinumab, used for
treating severe asthma. If successful, this would be the first companion diagnostic test developed for asthma. Moreover, AstraZeneca
expects half of its drug launches to include companion diagnostic by 2020. This is a major factor implying the importance of companion
diagnostics in treating chronic diseases.
REPORT DESCRIPTION
Simultaneous development of a companion diagnostic test and the drug candidate has its own set of pros and cons that act as a trade-off
for pharmaceutical companies. Developing companion diagnostic risks holding up of effective drug therapies, and making major
investments on companion diagnostics early is a perceived risk, as many drug candidates fail to make it to the market. However,
personalized medicine is the emerging therapeutic approach for cancer and other chronic therapies. Thus, developing a companion
diagnostic for faster FDA approval makes it imperative for researchers to invest in the development of CDx tests.
Agilent technologies, Inc. announced the extended use of its CE approved Dako PD-L1 IHC 22C3 pharmDx in January 2017, in determining
PD-L1 expression status in patients with metastatic non-small cell lung cancer (NSCLC). This device helps determine the expression level of
PD-L1 in both untreated and previously treated metastatic NSCLC patients with KEYTRUDA (pembrolizumab), a first-line treatment drug for
metastatic NSCLC. With this approval, patients with metastatic NSCLC and in the second-line or later treatment settings can also be
identified for treatment with KEYTRUDA.
To know the latest trends and insights prevalent in the companion diagnostic market, click the link below:
https://www.coherentmarketinsights.com/market-insight/companion-diagnostics-market-109
Invivoscribe Technologies Inc., has companion diagnostics development deal with Novartis AG and Astellas Pharma Inc. Invivoscribe
Technologies Inc. has developed a companion diagnostic test for FLT3, a biomarker for the stratification and prognosis of acute myeloid
leukemia (AML). This CDx is under the U.S. FDA review for its use with PKC412 (midostaurin) an investigational drug for adults with newlydiagnosed AML and who are FLT3 mutation-positive. If granted approval the LeukoStrat CDx FLT3 Mutation Assay would be the first CDx for
AML.
Approval of the drug and CDx test at the same time is difficult. However, the endeavor to develop effective targeted therapies at low cost
and faster time to market would encourage more drug developers to conduct clinical trials with diagnostics as part of the
inclusion/exclusion criteria.
REPORT DESCRIPTION
Key takeaways of the market:
• The global companion diagnostic market is expected to expand at a CAGR of 12% during the forecast period (2016–2024). Improved
clinical outcomes, reduced total research cost and faster time to market are some of the major factors driving collaborations and CDx
development globally
• The breast cancer application in the global CDx market was estimated to be the largest in 2015 and is expected to dominate the market
throughout the forecast period in terms of value. This is owing to high number of approved brands with CDx tests, driving adoption of
these products in treatment of breast cancer.
• In terms of technology, the gene sequencing method segment is expected to expand at a CAGR of 12.6% during the forecast period.
Growth of the segment is mainly attributed to increasing focus on identification of genetic mutations that can help in precise
identification of the treatment approach for cancer therapies.
• The global companion diagnostics market is characterized by strategic research and development collaborations among the drug and
diagnostic test developers. According to the Wildwood Ventures Ltd., the number of global deal in CDx market has increased from 13 in
2007 to 66 in 2013.
Enquire Before Buying this Exclusive Report by CMI : https://www.coherentmarketinsights.com/insight/requestsample/109
Some of the major players are Abbott Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare, Qiagen N.V., Roche
Diagnostics, Biomérieux, Myriad Genetics, Inc., bioMérieux SA, and Siemens Healthcare
Request Customization this Exclusive Report bt CMI : https://www.coherentmarketinsights.com/insight/requestcustomization/109
ABOUT COHERENT MARKET INSIGHTS
ABOUT US
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve
transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global
financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are
uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about
operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated
market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study
emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES
INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
ABOUT CMI
SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
 Global Leading Equipment and System Manufacturers
 Marketing Consultancies and the Advertising Industry
 Component Providers and System Integrators
 Private and Government organization
 Distributors, Retailors and Value Added Resellers
 Outsourcing Companies
 Healthcare IT Solutions Developers
 Universities and Business Schools.
ABOUT US
KEY STATS
RESEARCH SOLUTIONS
FEASIBILITY
STUDIES
GLOBAL
REPORTS
100+
Insights Published Per Year
150+
Consulting Projects Till Date
125+
Clients Worldwide Per Year
110+
COUNTRY
ANALYSIS
CONSULT
PROJECTS
CUSTOMIZED
SOLUTIONS
SURVEY
RESEARCH
EXCEL
FORECAST
DATABASE
COMPETITIVE
ASSESSMENT
TECHNOLOGY
SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food &
beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various
industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients
achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in
developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein.
THANK YOU
To know more about us, visit our website:
www.coherentmarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact:
Mr. Shah
(Manager - Business Development)
Coherent Market Insights
[email protected]
+1-206-701-6702

The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic test products.

Download Report